Literature DB >> 2531107

Plasmid vectors for constructing translational fusions to the B subunit of cholera toxin.

M T Dertzbaugh1, F L Macrina.   

Abstract

A family of plasmid cloning vectors has been developed for creating translational fusions to the ctxB gene encoding the B subunit of cholera toxin (CTB) in Escherichia coli. These vectors permit insertion of transcriptionally and translationally competent gene sequences upstream from ctxB. To test the utility of the system, a portion of the glucosyltransferase B (GTF) gene (gtfB) from the cariogenic bacterium Streptococcus mutans GS-5 (Bratthall serotype c), encoding the N-terminal one-third of the protein, was inserted into each vector. E. coli lysates containing the constructs were partially purified by passage over a GM1 ganglioside affinity column. Western blotting analysis of the column retentate from one of the lysates revealed the presence of a novel 58-kDa protein which cross-reacted with antisera to GTF and CTB. These vectors are of general use for making other translational fusions to ctxB. The high binding affinity of CTB can be exploited in purifying large polypeptides fused to this relatively small protein. Moreover, these vectors can be used to create neoantigens with altered immunogenicity for use in polypeptide-based vaccines.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2531107     DOI: 10.1016/0378-1119(89)90060-7

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  12 in total

1.  Cholera toxin B-subunit gene fusion: structural and functional analysis of the chimeric protein.

Authors:  M T Dertzbaugh; D L Peterson; F L Macrina
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

Review 2.  Progress towards development of a vaccine for amebiasis.

Authors:  S L Stanley
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

3.  Reduction in oral immunogenicity of cholera toxin B subunit by N-terminal peptide addition.

Authors:  M T Dertzbaugh; C O Elson
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

4.  Protection of gerbils from amebic liver abscess by vaccination with a 25-mer peptide derived from the cysteine-rich region of Entamoeba histolytica galactose-specific adherence lectin.

Authors:  H Lotter; F Khajawa; S L Stanley; E Tannich
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

5.  Gene therapeutic approach to primary and metastatic brain tumors: I. CD44 variant pre-RNA alternative splicing as a CEPT control element.

Authors:  D C Asman; J F Dirks; L Ge; N M Resnick; L A Salvucci; J T Gau; M J Becich; D L Cooper; G J Dougherty
Journal:  J Neurooncol       Date:  1995-12       Impact factor: 4.130

6.  Induction and recall of immune memory by mucosal immunization with a non-toxic recombinant enterotoxin-based chimeric protein.

Authors:  Christine M Gockel; Michael W Russell
Journal:  Immunology       Date:  2005-12       Impact factor: 7.397

7.  Inhibition of Streptococcus mutans glucosyltransferase activity by antiserum to a subsequence peptide.

Authors:  M T Dertzbaugh; F L Macrina
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

8.  Oral immunization with the dodecapeptide repeat of the serine-rich Entamoeba histolytica protein (SREHP) fused to the cholera toxin B subunit induces a mucosal and systemic anti-SREHP antibody response.

Authors:  T Zhang; E Li; S L Stanley
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

9.  Immunologic characteristics of a Streptococcus mutans glucosyltransferase B sucrose-binding site peptide-cholera toxin B-subunit chimeric protein.

Authors:  P Laloi; C L Munro; K R Jones; F L Macrina
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

10.  A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity.

Authors:  S Yamamoto; H Kiyono; M Yamamoto; K Imaoka; K Fujihashi; F W Van Ginkel; M Noda; Y Takeda; J R McGhee
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.